Eli Lilly (LLY) stock slips as IQVIA data show that the company's obesity drugs Zepbound and Foundayo lag Novo’s (NVO) Wegovy in weekly prescriptions. Read more here.
Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy
Comments
(23)
Eli Lilly (LLY) fell in premarket trading after Bloomberg reported that weekly prescriptions for the company’s weight loss therapies, Foundayo and Zepbound, traile... [270 chars]